Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Purchased by Dillon & Associates Inc.

Key Points

• Dillon & Associates Inc. increased its stake in Intuitive Surgical by 6.4%, now owning 26,417 shares valued at approximately $13 million, making it the firm's 17th largest holding.
• Intuitive Surgical reported earnings of $2.19 per share, exceeding analyst expectations of $1.93, along with a revenue of $2.44 billion for the quarter, up 21.4% year-over-year.
• Analysts have mixed ratings for the stock, with price targets ranging from $440 to $600, highlighting its classification as a "Moderate Buy" by the consensus.

Dillon & Associates Inc. boosted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 6.4% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 26,417 shares of the medical equipment provider's stock after acquiring an additional 1,594 shares during the quarter. Intuitive Surgical accounts for about 1.9% of Dillon & Associates Inc.'s portfolio, making the stock its 17th biggest holding. Dillon & Associates Inc.'s holdings in Intuitive Surgical were worth $13,076,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Chilton Capital Management LLC boosted its stake in Intuitive Surgical by 614.3% during the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 43 shares during the last quarter. Parvin Asset Management LLC acquired a new stake in Intuitive Surgical during the 4th quarter worth $26,000. Global Financial Private Client LLC raised its holdings in shares of Intuitive Surgical by 253.3% during the 1st quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock worth $26,000 after acquiring an additional 38 shares during the period. Elite Financial Inc. purchased a new position in shares of Intuitive Surgical during the 1st quarter worth $26,000. Finally, LFA Lugano Financial Advisors SA purchased a new position in shares of Intuitive Surgical during the 1st quarter worth $30,000. Institutional investors and hedge funds own 83.64% of the company's stock.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock opened at $470.08 on Monday. Intuitive Surgical, Inc. has a one year low of $425.00 and a one year high of $616.00. The company has a market cap of $168.51 billion, a PE ratio of 65.56, a P/E/G ratio of 4.93 and a beta of 1.59. The business has a 50-day simple moving average of $516.52 and a 200-day simple moving average of $528.23.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, topping analysts' consensus estimates of $1.93 by $0.26. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%. The business had revenue of $2.44 billion during the quarter, compared to the consensus estimate of $2.35 billion. During the same period in the previous year, the company posted $1.78 earnings per share. The business's revenue for the quarter was up 21.4% on a year-over-year basis. On average, sell-side analysts predict that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on ISRG shares. UBS Group lifted their price target on Intuitive Surgical from $547.00 to $585.00 and gave the stock a "neutral" rating in a report on Wednesday, July 23rd. Robert W. Baird reduced their price target on Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating on the stock in a report on Wednesday, April 23rd. Deutsche Bank Aktiengesellschaft lowered Intuitive Surgical from a "hold" rating to a "sell" rating and reduced their price target for the stock from $515.00 to $440.00 in a report on Monday, June 9th. Erste Group Bank reiterated a "hold" rating on shares of Intuitive Surgical in a report on Wednesday, July 23rd. Finally, Truist Financial lifted their price target on Intuitive Surgical from $590.00 to $600.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. One analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, Intuitive Surgical has an average rating of "Moderate Buy" and a consensus target price of $595.95.

Insider Transactions at Intuitive Surgical

In related news, insider Gary S. Guthart sold 7,893 shares of the company's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $498.64, for a total value of $3,935,765.52. Following the completion of the transaction, the insider directly owned 13,187 shares of the company's stock, valued at $6,575,565.68. This represents a 37.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Myriam Curet sold 4,500 shares of the company's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $492.48, for a total value of $2,216,160.00. Following the completion of the transaction, the executive vice president directly owned 353 shares of the company's stock, valued at $173,845.44. This trade represents a 92.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 15,881 shares of company stock valued at $7,920,634. 0.70% of the stock is currently owned by corporate insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.